Similar articles

• Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

  Nash P, Thaçi D, Behrens F, Falk F, Kaltwasser JP. Nash P, et al. Dermatology. 2006;212(3):238-49. doi: 10.1159/000091251. Dermatology. 2006. PMID: 16549920 Clinical Trial.
• Leflunomide in psoriatic arthritis.

  Kaltwasser JP. Kaltwasser JP. Autoimmun Rev. 2007 Sep;6(8):511-4. doi: 10.1016/j.autrev.2006.12.001. Epub 2007 Jan 9. Autoimmun Rev. 2007. PMID: 17854740 Review.
• Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

  Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Antoni CE, et al. Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. Arthritis Rheum. 2005. PMID: 15818699 Clinical Trial.
• Treatment of severe psoriasis and psoriatic arthritis with leflunomide.

  Reich K, Hummel KM, Beckmann I, Mössner R, Neumann C. Reich K, et al. Br J Dermatol. 2002 Feb;146(2):335-6. doi: 10.1046/j.1365-2133.2002.4653_5.x. Br J Dermatol. 2002. PMID: 11903256 No abstract available.
• [Infliximab].

  Herrera E, Habicheyn S. Herrera E, et al. Actas Dermosifiliogr. 2008 Jul;99 Suppl 4:7-13. Actas Dermosifiliogr. 2008. PMID: 19080986 Review. Spanish.